Monitor enrollment updates and interim data from SOLARA; the single-arm design and FDA's prior recommendation for a randomized trial introduce regulatory risk. Positive Phase 3 results could support a BLA submission and transform Hemab's commercial prospects in GT.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $42.81entry
- T+1 · 7d ago −9.44%α −9.07% · $38.77
- T+5 · 16h ago −8.77%α −7.08% · $39.06
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial of sutacimig (HMB-001) for prophylactic treatment of Glanzmann thrombasthenia, a rare bleeding disorder with no approved prophylactic therapy. The single-arm, intra-participant controlled trial will enroll ~75 participants, with a 24-week run-in followed by 48 weeks of treatment. The FDA recommended a randomized design but acknowledged feasibility concerns; Hemab proceeded with a single-arm design. The trial builds on Phase 2 data showing a 62% reduction in high-intensity annualized treated bleed rates.
Key Facts
- First participants consented for SOLARA Phase 3 trial of sutacimig in Glanzmann thrombasthenia (GT)
- Single-arm, open-label trial with 24-week run-in and 48-week treatment; primary endpoint is annualized treated bleed rate
- Phase 2 data showed 62% reduction in mean high-intensity annualized treated bleed rate and 92% of participants had reduced treated bleed rates
- FDA granted Fast Track, Orphan Drug, and Breakthrough Therapy Designations for sutacimig in GT
- No approved prophylactic treatment currently exists for GT
Financial Impact
First pivotal trial for a potential first-in-class prophylactic therapy in an orphan indication with no approved treatment; market cap $2.1B
Risk Factors
- FDA recommended a randomized controlled design; Hemab's single-arm approach may face regulatory hurdles for approval
- Thromboembolic events observed in Phase 2 at higher exposures; dose selection aims to mitigate but risk remains
- Small trial size (n=75) and rare disease may limit statistical power and generalizability
- Document contains text addressed to automated readers (forward-looking statements boilerplate)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398220 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers